patients, both at the 700mg cyclophosphamide dose level with thromboembolic complications in 6% of patients. The overall complete remission rate was 29%, very good partial remission rate 7% and partial remission rate 45% giving an overall response rate of 81%. After a median follow-up of 21 months, projected 2 year progression free survival (PFS) is 56% and the overall survival at 30 months is 80%. 10 patients were treated in an extended cohort group at the maximum tolerated dose of cyclophosphamide with a 40% CR rate. No dose reductions for any of the study drugs or deaths was required during cycles 1-9. The combination of Lenalidomide, cyclophosphamide and dexamethasone is a safe and effective combination in relapsed myeloma inducing a high response rate that are durable and warrants further investigation in the phase 3 setting. Immunomodulatory (IMiD) drugs are an important set of molecules in the management of myeloma patients. Thalidomide was first shown to be effective in relapsed/refractory myeloma (Singhal, et al 1999) with responses of partial response (PR) or greater being seen in >20% of patients (YakoubAgha, et al 2002) . Based on these and subsequent studies, thalidomide is currently used at all disease stages and often in combination with a steroid and alkylating agent. More recently, the role of Lenalidomide (Revlimid), a more potent IMiD, has been explored in patients with relapsed myeloma in two identical phase 3 studies (Dimopoulos, et al 2007 , Weber, et al 2007 .
These studies compared Lenalidomide/Dexamethasone with Dexamethasone alone and demonstrated the combination improved progression free and overall survival.
Alkylating agents have been the standard of care for myeloma patients for many years with Melphalan and Prednisolone being considered the standard approach for patients not destined for autologous transplantation. A series of clinical trials performed in the UK in the 1980s, demonstrated the equivalent efficiency of cyclophosphamide to melphalan and highlighted its favourable toxicity profile with less profound myelosuppression (Augustson, et al 2005) , lacking the stem cell toxicity of melphalan, making it safe to use in patients destined for transplant (Child, et al 2003) . In addition, cyclophosphamide has a large non-renal component of elimination making it a safer drug for patients with renal impairment. Combination chemotherapy regimen exploiting synergistic affects of the individual components are often highly effective in oncology and there is a need to develop effective combinations for patients with myeloma.
The addition of an alkylating agent to standard chemotherapy (CVAMP), thalidomide (CTD or MTP) or bortezomib (MPV or CVD) has been shown to increase response rates and possibly to prolong survival (Berenson, et al 2006 , Kropff, et al 2007 , Palumbo, et al 2006 , Raje, et al 1997 , Sidra, et al 2006 . However, the optimal dose of cyclophosphamide in combination with lenalidomide, which is known to cause myelosuppression, has not yet been defined. The aims of this study were to develop a safe alkylating agent, Patients diagnosed as relapsed myeloma, at first or subsequent relapse, were eligible for the study but were excluded if they had received chemotherapy, including corticosteroids, within 28 days of the start of treatment. Local radiotherapy for symptom relief for previously recognised myeloma deposits was allowed before starting treatment but not to new sites of disease if they developed during the study which was classified as disease progression.
Patients were eligible if they had adequate renal function (serum creatinine <2 mg//dl) and bone marrow reserve (baseline platelet count >20 x 10 9 /l or absolute neutrophil count >1.0 x 10 9 /l). In addition, patients with grade 3 peripheral neuropathy or a history of other malignancy within 3 years were excluded.
Dose limiting Toxicity
Dose limiting toxicity (DLT) was defined as; Grade 4 haematological toxicity occurring during cycle 1, febrile neutropenia during cycle 1, grade 3/4 nonhaematological toxicity during cycle 1 (excluding alopecia), or failure to start cycle 2 within 7 days of scheduled day due to treatment related toxicity.
Providing no patient within a cohort experienced DLT, the subsequent cohort received an increased dose of cyclophosphamide. If one patient in a dose cohort experienced DLT, another three patients were enrolled at the same dose. If 2 or more of all 6 patients at that dose experienced DLT, the MTD would be determined as one cohort dose level below. If 1 or fewer of the 6 patients experienced DLT, three more patients were recruited into the subsequent, higher dose cohort, up to a maximum of 700mg. . 
Dose modification and withdrawal

Safety and Efficacy Assessment
Patients were assessed weekly during the first month of treatment and 4 weekly thereafter. Response was assessed prior to each course of treatment, using the international uniform response criteria (Durie, et al 2006) . Bone marrow aspirate/biopsy evaluations were carried out at trial entry and at discontinuation of treatment to confirm response. Adverse events were graded according to NCI common toxicity criteria (Version 3.0, Bethesda, MD, USA http:// ctep.cancer.gov/forms/ CTCv20_4-30-992.pdf). All patients who developed grade 4 haematological toxicity underwent bone marrow examination.
Statistical Analysis:
The primary outcome measures were toxicity and safety. The secondary endpoints were response, progression free and overall survival. The MTD was identified using arithmetic (or fixed) dose escalation. Response rates together with two-sided 95% confidence intervals were provided for all study endpoints based on categorised responses. Data from all subjects who received any study drug were included in the safety analyses. Overall 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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RESULTS
Patient Characteristics:
A total of 31 patients were enrolled into the study of whom 28 (90%) had previously received thalidomide, 8 (26%) bortezomib and 20 (65%) prior autologous stem cell transplant (Table 1 ). The median age at enrolment was 65 years (range 42 -79), median time since the last therapy 7 months (range 1 -84) and the median ISS 1 (range 1 -3). Five cohorts were enrolled at increasing doses of cyclophosphamide; Cohort 1 (300mg (n=3)), cohort 2 (400mg, (n=6)), cohort 3 (500mg (n=3)), cohort 4 (600mg (n=3)) and cohort 5 (700mg (n=6)). Median follow-up at time of analysis is 21 months. (22%) patients were shown to be in a cytogenetically poor risk category; 4 patients had del13, 2 had t(4:14), 5 had t(14:16) and 1 patient had a del17p.
Toxicity:
All patients were evaluable for toxicity during cycle 1 (Figure 1 , Table 2 ). Two patients developed grade 4 haematological toxicity in the cohort of patients receiving 700mg of cyclophosphamide (1 neutropenia and the other pancytopenia) and 3 other patients developed grade 3 neutropenia at a dose of 300, 400 and 600 mg. Two further patients developed grade 2 neutropenia at 600 and 700 mg and one other grade 2 neutropenia and anaemia at 400mg. One patient receiving 700mg developed grade 3 syncope, chest pain and pneumonia and was withdrawn from study. Haematological toxicity was therefore established as the dose limiting toxicity (DLT). The maximum tolerated dose of cyclophosphamide in combination with Lenalidomide and dexamethasone was, established at 600mg daily on days 1 and 8 of a 28 day cycle. A total of 10 more patients were enrolled into the phase 2 part of the study at the 600mg dose level, and, of these, none experienced a dose limiting toxicity.
During the extended access phase of the study 10 patients (32%) developed grade 3 cytopenia in the absence of progressive disease; during cycle 2-5.
Two patients in CR developed transient grade 3 neutropenia during cycles 9
and 15 of maintenance both of whom restarted after a 1 week delay. A further developed grade 3 cardiac arrhythmias, 1 a bradycardia during cycle 5 necessitating withdrawal from the study and another developed atrial fibrillation during cycle 3 necessitating discontinuation of treatment before being able to restart at the same dose level. No grade 3-4 neurological toxicity was reported but 2 patients (6%) reported emergent grade 1-2 peripheral neuropathy. Treatment was not discontinued and both patients reported no progression with continuing treatment.
To date, a total of 13 patients have been withdrawn from study, 8 were withdrawn during the induction phase; 3 because of disease progression, 1 with infection; 1 with diabetes mellitus; 1 with an arrhythmia and 2 developed cytopenias. A further 5 patients were withdrawn during the maintenance courses of induction treatment. At the end of the planned 9 cycles of treatment 13 (40%) patients continued on Lenalidomide 25mg, 2 (6.5%) on 20mg and 4 (12%) on 15 mg of daily (Figure 2 ). The most common reason for dose delay and reduction during the first month of treatment was grade 3 neutropenia.
There were 9 infectious events reported; 7 grade 1, 1 grade 2, and 1 grade 3 occurring at the maximum dose of 700mg cyclophosphamide (fig 2) . The most commonly observed adverse events were; neutropenia (grade 1-3), cramps (grade 1-2), somnolence (grade 1-2), constipation/diarrhoea (grade 1-2), minor infections (grade 1-2), and musculo-skeletal aches and pains (grade 1).
Determination of MTD:
During the first 28 days of the study, 2 patients developed a dose limiting toxicity, both of whom were in the 700mg cyclophosphamide cohort. One had an episode of febrile neutropenia, pneumonia and syncope (all grade 3), and the other grade 4 pancytopenia. The maximum tolerated dose of cyclophosphamide in combination with lenalidomide and dexamethasone was, therefore, established at 600mg daily on days 1 and 8 of a 28 day cycle.
Clinical Response:
All patients were evaluable for response. At cycle 1 day 28, 4 patients (13%) had stable disease (SD), 10 (33%) had a minimal response (MR), 16 (53%) had a PR and 1 patient (3%) achieved a CR. After 9 courses of treatment, the maximum responses seen were CR 29%, VGPR 7%, PR 45%, MR 3%, SD (fig 3) . By the end of course 6 a maximum response was achieved by 27 patients (90%), (Figure 3 ). All patients achieved their maximum response by this time point and no patients had a further improvement in their response following commencement of maintenance therapy. Thus, on an intention to treat basis, 81% of patients achieved a maximum response of PR or greater and 36% >VGPR.
Of the ten patients entered into the maximum tolerated dose cohort, 6
achieved PR, and 4 achieved CR. One patient was withdrawn due to progressive disease at cycle 11 of maintenance. There were no deaths and no dose reduction of any study drugs was performed during cycles
1-9.
There was no difference in response rates between those patients with cytogenetic abnormalities and those without (p=0.73) and similarly, the response for those patients with serum beta 2 microglobulin <2.5 were not statistically different from those with levels of 2.5 or higher (p=0.03). There were a total of 12 patients who received cyclophosphamide at a dose of less than 600 mg and 19 patients who received a dose of 600mg or more. No significant differences in response rates were seen between these 2 groups.
After a median follow-up of 21 months, the actuarial median progression free survival (PFS) for the whole group was not reached (Fig 4) . At 2 years the PFS is estimated to be 56%. Median actuarial overall survival has also not been reached but was 80% at 30 months (Fig 5) . The 1 patient with deletion of 17p53 achieved a PR after 2 courses of treatment and has a progression free interval of 17 months. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w seen in MM009 and MM010 studies, suggesting that cyclophosphamide does not add significantly to haematological toxicity. The toxicity profile also seems to differ from the combination of melphalan and prednisolone with Lenalidomide where Grade 3-4 haematological toxicity at a level of 52.4% was seen at the maximum tolerated dose level (Palumbo, et al 2007) . The difference in myelosuppression with cyclophosphamide compared to melphalan is consistent with the CRD combination being a safer and more tolerable regimen than MPR.
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The addition of cyclophosphamide in this study has increased the overall response rate [CR + VGPR + PR] to 81% which is superior to that reported for Lenalidomide alone (17%-23%) (Armoiry, et al 2008) or in combination with dexamethasone (48%-51%) (Wang, et al 2008) . These responses were observed despite the number of median lines of prior therapy of 3 (range 1-6), used in this study compared to that seen in the MM009 and MM010 trials where up to one third of patients were treated at first relapse.
These responses are also higher than our previously reported CR+PR response rates of 65% in a retrospective audit of patients receiving a combination of Lenalidomide, cyclophosphamide and dexamethasone (Morgan, et al 2007) , all of whom had end-stage disease.
Responses after relapse from first line treatment for myeloma are generally short-lived, with outcomes being determined by the presence of adverse comorbidities, cytogenetic abnormalities and the adverse side-effects profile of re-induction treatment. In both first and subsequent relapses, increasing drug resistance and accumulated myelo-and nephrotoxicity restrict the intensity of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Augustson, et al 2005) showed that the median OS of the 1372 patients who achieved plateau was 3.9 years. At relapse, for those with 1 prior therapy it was 16.1 months and 9.2 for ≥2 prior therapies. If duration of response is taken into account in those whose duration of plateau phase was <1 yr, 1-3 yrs and >3 yrs, the median survivals from relapse were 11, 17 and 21 months, respectively. The mean duration of survival at first, second and third plateau were 4.8, 2.0 and 1.0 years respectively. In a more recent study of patients with relapsed/refractory disease (Quach, et al 2009) , progression free survival beyond 2 years was seen in only 27/141 (19%). The predicted two year PFS of 56% within the CRD combination would support the hypothesis that Revlimid adds significantly to the effects of cyclophosphamide and dexamethasone alone and represents a significant step forward.
It has been suggested (Stewart, et al 2007) that the presence of t(4;14), t(14;16), t(14;20) and del17p13 on FISH and del 13 on metaphase cytogenetics are associated with high risk disease. Although the numbers are too small to draw firm conclusions, a quarter of patients in this study were classified as high risk, but there was no difference seen in response to treatment compared to standard risk patients (93% versus 85%; data not shown). Similar results have been reported by the Canadian group . Our results support these findings they need to be confirmed in 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 associated with a response rate of 75% and CR/nCR rate of 29% but the maximum tolerated dose of Lenalidomide was only 10mg /day (Baz, et al 2006) . More recently, a Phase I/II study by the German Myeloma Study Group, DSMM (Knop, et al 2009) , using Lenalidomide in combination with dexamethasone, conventional doxorubicin and pegfilgrastim support, was associated with an ORR of 69% (CR+VGPR+PR). They further reported, at a median follow-up of 14.6 months a median time to disease progression of 45 weeks and the one year survival probability was 88%. In our study, the overall survival of 80% at 30 months is encouraging. The German Group further report a higher percentage of grade 3/4 neutropenia (48%) and thrombocytopenia (38%) compared to what we observed here in combination with cyclophosphamide. The thromboembolic complication rate we report is similar to the DSMM study, but grade 3/4 infections were less common (3% vs 10%).
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